Anticoagulant Eliquis has taken the U.S. warfarin alternative market by storm, passing warfarin itself in the process. But the drug's marketers, Bristol-Myers Squibb and Pfizer, believe advanced ...
Pfizer and Bristol-Myers Squibb’s next-gen anticoagulant Eliquis grabbed a commanding lead over its competitors—even topping longtime U.S. market leader warfarin. Not content to rest on its laurels, ...
In everyday practice, patients with atrial fibrillation or flutter who are newly started on apixaban (Eliquis; Bristol-Myers Squibb) have lower ischemic and bleeding risks compared with those started ...
TRENTON, N.J. (AP) — Regulators in Japan have approved sales of an anticlotting drug called Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc., that’s a potential blockbuster in a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results